To the Market

The European Commission has given its seal of approval to the continent’s first gene therapy — a treatment for a lipid-processing disorder — which will be sold in Europe beginning in late 2013, The Scientist reports.

According to the article, the EC has approved the use of Glybera, a therapy that “utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a gene mutation.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

This Week in Science

This Week in PLOS

Highs and Lows

Don't Chew The Pills!

Faster Turnaround

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.